NextPharma Technologies Receives Full Approval from Austrian Regulatory Authorities for its Expanded Temperature Controlled Storage Facilities in Stockerau, Austria
Published: Jan 20, 2010
Surrey, UK, 20th January, 2010 - NextPharma Technologies, a leading provider of pharmaceutical product development, contract manufacturing, cold chain and distribution outsourcing services, is pleased to announce that the expansion of its Cold Chain and Logistics (CLS) business in Austria has received full regulatory approval and has been granted a Distributors-Manufacturers License by the Austrian ‘Federal Office for Safety in Healthcare’. The warehouse expansion has created a 2,200 square metre cGMP compliant facility with an additional 3,500 pallet spaces, temperature controlled storage at 15 - 25 °C and 280 cold storage pallet places at 2 - 8 °C. As a result of this expansion NextPharma Austria now provides approximately 7,500 pallet places for the distribution of pharmaceuticals and other healthcare products in Austria and its surrounding countries. Jost Bunse, Managing Director, NextPharma Technologies, CLS commented “there has been rapid growth in demand for our services and we are delighted to be in a position where we can provide our customers with this extended operation to enable them to secure their growth strategies”. Bill Wedlake, CEO, NextPharma Technologies commented “the approval of our expanded Austrian temperature controlled storage facilities is an important step in the expansion of NextPharma’s Cold Chain and Logistics business”. NextPharma Austria also provide services that cover the total ‘order-to-cash’ cycle for our customers, e.g. order taking, administration and cash collection. Value added services like manual re-packaging, return handling and worldwide export processing are part of our service portfolio. CLS across NextPharma NextPharma CLS provides ‘one stop’ logistics solutions tailored to meet the needs of the international pharmaceutical and biotechnology industries under the rigid standards of cGSP/GDP regulations. It is supported by state-of-the-art technology with controlled room temperature storage from 15°C to 25°C down to minus 80°C. Its pick, pack and ship systems ensure the correct product reaches its destination according to the requirements of our customers. This pre-wholesaling business delivers directly to pharmacies, hospitals, doctors, sales representatives and wholesalers. Customers also benefit from NextPharma's economies of scale. Logistics services include importation, receipt of goods, storage, order administration, processing of returns, pick, pack, ship/dispatch, accounting, invoicing and debt collection. NextPharma uses sophisticated Information Technology (IT) systems to provide customers seamless communication with its sites. NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines. About NextPharma NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry. We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture. We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan. We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies. All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.